3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
3
Completed
2
Active not recruiting
2
Withdrawn
1
Unknown
1
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Neoplasm Metastasis
6
Lymphoma, Extranodal NK-T-Cell
6
Carcinoma, Hepatocellular
5
Stomach Neoplasms
3
Nasopharyngeal Carcinoma
3
Locally Advanced Rectal Cancer
3
Colorectal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Advanced Solid Tumor
3
Triple Negative Breast Neoplasms
2
Pancreatic Neoplasms
2
Neoplasms
2
Nasopharyngeal Neoplasms
2
Melanoma
2
Epstein-Barr Virus Infections
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor
1
Sarcoma
1
Recurrence
1
Rectal Neoplasms
1
Pancreatic Adenocarcinoma Metastatic
1
Osteosarcoma
1
Objective Response Rate
1
NSCLC
1
Muscle-Invasive Bladder Carcinoma
1
Lymphoma, T-Cell
1
Lymphoma
1
Kidney Neoplasms
1
Immunoblastic Lymphadenopathy
1
Interventions
Cisplatin
44
Paclitaxel
21
Radiotherapy
20
Brachytherapy
19
Carboplatin
18
Bevacizumab
7
Drug Therapy
6
camrelizumab
5
toripalimab
4
nimotuzumab
4
Radiation
4
Neoadjuvant Therapy
4
Gemcitabine
4
tislelizumab
3
sintilimab
3
pembrolizumab
3
apatinib
3
Vaccines
3
TP protocol
3
Surgical Procedures, Operative
3
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
3
nedaplatin
2
fludarabine
2
endostar protein
2
anlotinib
2
Topotecan
2
Surveys and Questionnaires
2
Sentinel Lymph Node Biopsy
2
Radiotherapy, Intensity-Modulated
2
Mindfulness
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Uterine Cervical Neoplasms
×
spartalizumab
×
Clear all
NCT04368273
2020-04-29
CCRT+PD-1
Peking University Third Hospital
Phase 1/2
Unknown
30 enrolled